CDKN2A-interacting protein (CDKN2AIP) (CDKN2AIP)

CDKN2A-interacting protein (CDKN2AIP), also known as Collaborative ARF Effector (CARF), is a critical regulatory protein that modulates the p53-mediated tumor suppression pathway (UniProt Q9NRP7). It was originally discovered through its direct interaction with p14ARF, a tumor suppressor encoded by the CDKN2A locus, and it plays a pivotal role in controlling cell cycle progression, apoptosis, and cellular senescence (PubMed: 12105216). CDKN2AIP functions in a complex, dose-dependent manner; while it can act as a co-activator of p53 to promote growth arrest, its overexpression in certain contexts can lead to the sequestration of p53 or ARF, thereby inhibiting their tumor-suppressive functions (PubMed: 15632141). This dual nature suggests that CDKN2AIP can act as either a tumor suppressor or an oncogene depending on the cellular environment and its concentration levels. Dysregulation of CDKN2AIP has been observed in various malignancies, including hepatocellular carcinoma and breast cancer, where its expression levels often correlate with clinical outcomes (PubMed: 25670303). Although there are currently no FDA-approved drugs that specifically target CDKN2AIP, it is an area of active research for developing therapies that can restore p53 function in cancer cells. The protein's involvement in the DNA damage response and its interactions with other key regulators like MDM2 further underscore its potential as a therapeutic target and biomarker in oncology.

Other names

CARFCollaborative ARF effectorp14ARF-interacting proteinCDKN2AIP

Modulation of the ARF-p53 signaling axis to regulate cell cycle arrest and apoptosis